Daiwa Securities Group
AVIR icon

Daiwa Securities Group’s Atea Pharmaceuticals AVIR Stock Holding History

Daiwa Securities Group’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-242
Closed -$1K – 1214
2025
Q4 		$1K Hold
242
– – ﹤0.01% 1340
2025
Q3 		$1K Hold
242
– – ﹤0.01% 1301
2025
Q2 		$1K Hold
242
– – ﹤0.01% 1250
2025
Q1 		$1K Hold
242
– – ﹤0.01% 1215
2024
Q4 		$1K Hold
242
– – ﹤0.01% 1247
2024
Q3 		$1K Hold
242
– – ﹤0.01% 1244
2024
Q2 		$1K Hold
242
– – ﹤0.01% 1282
2024
Q1 		$1K Hold
242
– – ﹤0.01% 1290
2023
Q4 		$1K Hold
242
– – ﹤0.01% 1290
2023
Q3 		$1K Hold
242
– – ﹤0.01% 1238
2023
Q2 		$1K Hold
242
– – ﹤0.01% 1259
2023
Q1 		$1K Hold
242
– – ﹤0.01% 1242
2022
Q4 		$1K Hold
242
– – ﹤0.01% 1258
2022
Q3 		$1K Hold
242
– – ﹤0.01% 1271
2022
Q2 		$2K Hold
242
– – ﹤0.01% 1223
2022
Q1 		$2K Hold
242
– – ﹤0.01% 1241
2021
Q4 		$2K Buy
+242
New +$3.77K ﹤0.01% 1273

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Daiwa Securities Group's AVIR Position: Q1 2026 in Review

Daiwa Securities Group sold out of Atea Pharmaceuticals (AVIR) in Q1 2026, closing a stake of 242 shares — an estimated $1K sold.

Daiwa Securities Group first reported a position in AVIR in Q4 2021 and held it in 17 quarters. The position peaked at $2K in Q2 2022. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • Daiwa Securities Group reported no remaining Atea Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 242 Atea Pharmaceuticals shares in Q1 2026, an estimated $1K.
  • Daiwa Securities Group first reported a position in Atea Pharmaceuticals in Q4 2021 and held it in 17 quarters.
  • Daiwa Securities Group's Atea Pharmaceuticals position peaked at $2K in Q2 2022.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.